The discovery that POLQ is a key prognostic biomarker in AML may have a therapeutic value because cancer cells, including AML cells overexpressing Polθ protein are hypersensitive to Polθ inhibitors which are currently in clinical trials against solid tumors [10, 15]. Here, POLQ is linked to acute myeloid leukemia.